Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TC-TLR7/8?
TC-TLR7/8 is a small molecule commercialized by Ascendis Pharma, with a leading Phase II program in Head And Neck Squamous...
Data Insights
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TC-TLR7/8?
TC-TLR7/8 is a small molecule commercialized by Ascendis Pharma, with a leading Phase II program in Vaginal Cancer. According to...